Sildenafil for Pulmonary Arterial Hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary hypertension (PH) is a severe condition leading to right heart failure.
• Increased pulmonary vascular resistance drives PH progression.
• Current treatments target endothelin, prostacyclin, and nitric oxide pathways.

Purpose of the Study:

• To review the emergence of sildenafil as a treatment for pulmonary arterial hypertension (PAH).
• To evaluate the role of sildenafil as palliative therapy in PAH management.

Main Methods:

• Literature review of phosphodiesterase-5 (PDE-5) inhibitors, specifically sildenafil.
• Analysis of FDA approval and clinical impact of sildenafil for PAH treatment.
• Summary of sildenafil's palliative effects on quality of life.

Main Results:

• Sildenafil (a PDE-5 inhibitor) was FDA-approved for PAH in 2005.
• Newer treatments have improved functional status and time to clinical worsening.
• Despite advances, patient outcomes remain suboptimal.

Conclusions:

• Sildenafil shows promise as an effective palliative therapy for PAH.
• It contributes to improving the quality of life for PAH patients.
• Further research may elucidate optimal use within evolving treatment paradigms.